首页> 外文期刊>Journal of Pharmaceutical Policy and Practice >Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods
【24h】

Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods

机译:使用层次分析法(AHP)和简单添加剂加权(SAW)方法在伊朗进行药品供应链风险评估

获取原文
           

摘要

Objectives Pharmaceutical supply chain is a significant component of the health system in supplying medicines, particularly in countries where main drugs are provided by local pharmaceutical companies. No previous studies exist assessing risks and disruptions in pharmaceutical companies while assessing the pharmaceutical supply chain. Any risks affecting the pharmaceutical companies could disrupt supply medicines and health system efficiency. The goal of this study was the risk assessment in pharmaceutical industry in Iran considering process's priority, hazard and probability of risks. Methods The study was carried out in 4 phases; risk identification through literature review, risk identification in Iranian pharmaceutical companies through interview with experts, risk analysis through a questionnaire and consultation with experts using group analytic hierarchy process (AHP) method and rating scale (RS) and risk evaluation of simple additive weighting (SAW) method. Results In total, 86 main risks were identified in the pharmaceutical supply chain with perspective of pharmaceutical companies classified in 11 classes. The majority of risks described in this study were related to the financial and economic category. Also financial management was found to be the most important factor for consideration. Conclusion Although pharmaceutical industry and supply chain were affected by current political conditions in Iran during the study time, but half of total risks in the pharmaceutical supply chain were found to be internal risks which could be fixed by companies, internally. Likewise, political status and related risks forced companies to focus more on financial and supply management resulting in less attention to quality management.
机译:目标药品供应链是医疗系统中药品供应的重要组成部分,特别是在当地药品公司提供主要药品的国家。以前没有研究评估药品供应链时评估制药公司的风险和中断。影响制药公司的任何风险都可能破坏供应药品和卫生系统的效率。这项研究的目的是考虑过程的优先级,危害和风险可能性,对伊朗制药业进行风险评估。方法研究分四个阶段进行。通过文献审查进行风险识别,通过与专家的访谈在伊朗制药公司中进行风险识别,通过问卷调查进行风险分析并使用群体层次分析法(AHP)和评级量表(RS)与专家进行咨询以及简单添加剂加权(SAW)的风险评估) 方法。结果从制药公司分类为11类的角度来看,在药品供应链中总共识别出86种主要风险。本研究中描述的大多数风险与金融和经济类别有关。财务管理也是最重要的考虑因素。结论虽然在研究期间,制药行业和供应链受到伊朗当前政治局势的影响,但发现制药供应链中总风险的一半是内部风险,这些风险可由公司内部解决。同样,政治地位和相关风险迫使公司更多地关注财务和供应管理,从而导致对质量管理的关注减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号